Shedding pounds, easing plaques: Weight management in psoriasis

We read with great interest the systematic review and meta-analysis article written by Morrow et al., which focussed on the effects of adjunct weight loss interventions in psoriasis.1 One of the key findings of the study is the improvement in Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores: weight-loss interventions were associated with an additional reduction of 2.5 points in PASI and almost 5 points in DLQI in the pooled values. While a reduction in PASI is small in absolute terms, the magnitude of the improvement is substantial.2-5 Also, the reduction in DLQI is close to a minimal important difference. These findings should be interpreted with some caution. The included studies were heterogeneous in terms of patient characteristics, baseline disease severity, intervention types and follow-up duration, and several trials carried a high risk of bias. The meta-analysis combined behavioural programmes, dietary interventions, exercise-based approaches and pharmacological therapies. While subgroup analyses did not show statistically significant differences between intervention types, mechanisms of benefit may differ. Behavioural interventions, particularly those incorporating structured exercise, may provide additional metabolic, anti-inflammatory and psychological benefits beyond weight reduction. Pharmacological agents, such as glucagon-like peptide-1 (GLP-1) receptor agonists, may exert pleiotropic effects on metabolism and inflammation but could also introduce other systemic effects. Thus, while weight loss is likely a key mediator of improvement, intervention type may also contribute to outcomes and deserves further exploration. From a clinical perspective, these results support integrating weight management into therapeutic strategies for psoriasis. Current evidence mainly supports weight loss as an adjunct to established systemic or topical therapies, as most trials combined interventions with ongoing treatment. Nevertheless, substantial weight reduction alone can lead to marked improvement in some patients, raising an important question regarding treatment sequencing: whether weight management should be introduced early—potentially before escalation to systemic therapy—in patients with obesity. Beyond dermatologic benefits, weight reduction addresses prevalent comorbidities, including metabolic syndrome, hypertension and possibly depression, underscoring its role in holistic patient care. The review also points to the possibility of applying pharmacological weight-loss therapy, such as GLP-1 receptor agonists liraglutide and semaglutide. Although the evidence is limited, the potential benefits of this approach are promising, as it demonstrates combined weight loss and anti-inflammatory properties, thus filling a niche in the treatment of patients with psoriasis and obesity. However, the sustainability of weight loss in the long run, as well as the benefits to those with psoriasis, is not known. The studies were of short duration, and weight loss relapse after a lifestyle intervention is common. This again points to the importance of understanding weight management as a long-term process, not a short-term one. An additional important implication concerns patient engagement. While obesity is a sensitive topic in clinical practice, many patients with psoriasis are highly motivated to identify strategies that allow them to actively contribute to improving their disease. Weight-management interventions may therefore represent an opportunity rather than a barrier in the therapeutic dialogue. Encouraging patients to participate in lifestyle or weight-management programmes can shift the treatment dynamic from passive disease management towards a collaborative model in which physician and patient work together to improve outcomes. In conclusion, the study by Morrow et al. contributes to the evidence for the effectiveness of weight management in the care of patients with psoriasis. Although weight loss is not likely to replace conventional treatments, it could potentially complement these treatments in an important way. The long-term effects of weight loss, the role of new pharmacotherapies, and how weight management can be incorporated into the care of patients with psoriasis are all worthy of further study. None. None to declare. Not applicable. Not applicable. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.